FGEN:NSD-FibroGen, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 18.57

Change

-0.24 (-1.28)%

Market Cap

USD 1.72B

Volume

4.06M

Average Target Price

USD 40.33 (+117.20%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.07 (+1.46%)

USD54.66B 20.44 15.09
MRNA Moderna, Inc

+7.04 (+5.26%)

USD53.62B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

-1.19 (-0.25%)

USD51.03B 15.61 12.36
ALXN Alexion Pharmaceuticals, Inc

+0.54 (+0.35%)

USD33.96B 56.79 33.32
BGNE BeiGene, Ltd

-6.35 (-2.02%)

USD29.36B N/A N/A
BNTX BioNTech SE

+7.65 (+6.68%)

USD27.29B -99,999.99 N/A
SGEN Seagen Inc

-1.62 (-1.12%)

USD26.58B 43.50 36.12
RPRX Royalty Pharma plc

+0.37 (+0.88%)

USD25.46B 22.60 15.46
GMAB Genmab A/S

+0.58 (+1.73%)

USD21.63B 26.59 3.09
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing FGEN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -49.93% 3% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.93% 3% F 2% F
Trailing 12 Months  
Capital Gain -49.00% 7% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.00% 7% F 2% F
Trailing 5 Years  
Capital Gain -12.65% 47% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.65% 47% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain 31.29% 65% D 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.29% 65% D 80% B-
Risk Return Profile  
Volatility (Standard Deviation) 61.14% 49% F 26% F
Risk Adjusted Return 51.18% 78% C+ 72% C-
Market Capitalization 1.72B 81% B- 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 85.04 12% F 15% F
Price/Book Ratio 7.74 32% F 24% F
Price / Cash Flow Ratio 21.11 5% F 22% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -38.76% 69% D+ 27% F
Return on Invested Capital -40.26% 60% D- 20% F
Return on Assets -14.24% 78% C+ 25% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.18 29% F 14% F
Short Percent 10.62% 28% F 19% F
Beta 1.19 64% D 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector